An understanding of the unique nature of single-use systems, and how they interact with each biomanufacturing process, is important when qualifying single-use systems.
The polymeric nature of single-use systems creates the potential for extractables and leachables to impact the production of drug products. The qualification of single-use systems is, therefore, different and more challenging than stainless-steel systems.
BioPharm International spoke with Andrew Bulpin, head of process solutions for MilliporeSigma; Danny Hower, extractables & leachables supervisor, SGS; Dr. Dujuan Lu, extractables & leachables technical client manager, SGS; Helene Pora, vice-president, technical communication and regulatory strategy, Pall Biotech; Eric Isberg, director of Life Sciences at Entegris; and experts from the Bio-Process Systems Alliance (BPSA) Technical Committee, about the challenges and procedures involved in the qualification of single-use systems.
Read this article in BioPharm International's Single-Use Systems 2018 eBook.
BioPharm International
eBook: Single-Use Systems
Vol. 31
June 2018
Pages: 18-23
When referring to this article, please cite it as S. Haigney, "Qualification of Single-Use Systems," BioPharm International Single-Use Systems eBook (June 2018).
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.